Powering Canada’s Future: Ensuring Access to Affordable, Reliable and Clean Electricity in New Brunswick
DIEPPE, NB, Dec. 8, 2024 /CNW/ – In the 21st century, a reliable and affordable clean electricity grid is the backbone of a strong economy. Today more than... Read more.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based... Read more.
Riyadh Action Agenda Gathers Steam as Land Governance Takes Center Stage at UNCCD COP16
RIYADH, Saudi Arabia, Dec. 8, 2024 /PRNewswire/ — The role of governance in local, regional and international efforts to tackle land degradation, drought and... Read more.
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine... Read more.
Blueprint Medicines’ Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
— ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM — — Bone density analyses reported... Read more.
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved... Read more.
Researchers Report New Opportunities to Improve Quality of Life for People with Non-Malignant Blood Disorders
Studies show promising new options to address unmet needs in sickle cell disease and immune thrombocytopenia SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — Researchers... Read more.
Blokees’ Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
SHANGHAI, Dec. 7, 2024 /PRNewswire/ — During the two-day 2024 Singapore Comic Con (December 7–8), Blokees unveiled its new Sesame Street collection for... Read more.
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new... Read more.
Calhoun County E911 Becomes First to Launch Ryzyliant’s Solution with INdigital NGCS Support
CALHOUN COUNTY, Ga. and FORT WAYNE, Ind., Dec. 6, 2024 /PRNewswire/ — Calhoun County E911 has achieved a significant milestone in November as the first in... Read more.